Skip to main content
OpenTrials
Completed

NCT Number: NCT04663672

Efficacy of Targeted Memory Reactivation for Enhancing Exposure Therapy

This study evaluates whether a scent applied during exposure therapy and during subsequent sleep will increase the durability of treatment effects for individuals with fear of spiders, contamination, and enclosed spaces.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Laboratory for the Study of Anxiety Disorders, University of Texas at Austin

Austin, Texas, 78712, United States

About this study

Newly acquired memories encoded during wakefulness are spontaneously re-activated during sleep, resulting in synaptic potentiation and strengthening of the re-activated traces. Targeted memory reactivation (TMR) typically involves a period of initial learning in the presence of an olfactory or auditory contextual cue, coupled with later presentation of the cue during sleep to ostensibly facilitate memory reactivation and consolidation. Numerous studies have found evidence of improved task performance subsequent to cue-induced neuronal replay, however application of TMR to treatment of naturally acquired, clinically significant fear has been limited.

The present study will will provide a rigorous test of TMR's efficacy as an augmentative strategy for exposure therapy. It is hypothesized that participants who sleep in the presence of the same odor that they are exposed to during exposure therapy will exhibit reduced fear at follow up, relative to participants who sleep in the presence of a different odor, or a non-odorous control.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Marked anxiety in at least one fear domain (spiders, contamination, or enclosed spaces), as determined by the presence of both:
  • self-reported peak anxiety of at least 50 on a 100 point scale in response to two behavioral approach tasks
  • self-report measures meeting the following cutoffs for the target fear:
  • Fear of Spiders Questionnaire ≥ 50
  • Obsessive-Compulsive Inventory-Revised (Washing Subscale) ≥ 4
  • Claustrophobia Screener ≥ 2

Exclusion criteria

  • Diagnosed sleep disorder
  • Current sleep medication usage
  • Inability to differentiate two different odors from an indoor scent diffuser
  • Current psychotherapy for fear of spiders, snakes, enclosed spaces, or contamination
  • Current use of air fresheners, scented candles, or other items with odors related to those used in the study

Treatment and study plan

Experimental Scent

Other

Participants will sleep in the presence of the exposure scent, delivered by an Airwick Essential Oils diffuser

Control Scent

Other

Participants will sleep in the presence of a novel scent, delivered by an Airwick Essential Oils diffuser

No-Scent Control

Other

Participants will sleep in the presence of an odorless control vehicle, delivered by an Airwick Essential Oils diffuser

In-vivo exposure

Behavioral

Participants will receive 40 minutes of in-vivo exposure therapy to feared targets in the presence of a distinctive exposure scent.

Primary outcomes

  1. Change in fear response during two behavioral approach tasks across time points

    Time frame: Baseline (Day 1); Post-treatment (Day 1; immediately after treatment); One Week Follow-Up (Day 8; one week after treatment); One Month Follow-Up (Day 31; one month after treatment)

    Change in subjective units of distress (0 = no fear, to 100 = extreme fear) and skin conductance in response to approaching a feared stimulus, from baseline to one month follow-up

Secondary outcomes

  1. Change in arachnophobia symptom severity across time-points

    Time frame: Baseline (Day 1); One Week Follow-Up (Day 8; one week after treatment); One Month Follow-Up (Day 31; one month after treatment)

    Change in total score on the Fear of Spiders Questionnaire from baseline to one month follow-up

  2. Change in claustrophobia symptom severity across time points

    Time frame: Baseline (Day 1); One Week Follow-Up (Day 8; one week after treatment); One Month Follow-Up (Day 31; one month after treatment)

    Change in total score on the Claustrophobia Questionnaire from baseline to one month follow-up

  3. Change in contamination fear symptom severity across time points

    Time frame: Baseline (Day 1); One Week Follow-Up (Day 8; one week after treatment); One Month Follow-Up (Day 31; one month after treatment)

    Change in total score on the contamination subscale of the Padua Inventory- Washington State University Revision from baseline to one month follow-up

Sponsors and collaborators

Lead sponsor

University of Texas at Austin

Other

Registry information

Official study title

Placebo-Controlled, Randomized, Double-Blind Study of the Efficacy of Targeted Memory Reactivation for Enhancing Exposure Therapy

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Dec 11, 2020
Registry last updated
Dec 11, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.